HUP0101128A2 - Lipáz enzimeket gátló polimerek alkalmazása elhízás elleni gyógyszerként - Google Patents

Lipáz enzimeket gátló polimerek alkalmazása elhízás elleni gyógyszerként

Info

Publication number
HUP0101128A2
HUP0101128A2 HU0101128A HUP0101128A HUP0101128A2 HU P0101128 A2 HUP0101128 A2 HU P0101128A2 HU 0101128 A HU0101128 A HU 0101128A HU P0101128 A HUP0101128 A HU P0101128A HU P0101128 A2 HUP0101128 A2 HU P0101128A2
Authority
HU
Hungary
Prior art keywords
inhibiting polymers
lipase inhibiting
anti obesity
obesity medicament
production
Prior art date
Application number
HU0101128A
Other languages
English (en)
Inventor
Molly Kate Boie
Venkata R. Garigapati
W. Harry Mandeville III.
Original Assignee
Geltex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharmaceuticals, Inc. filed Critical Geltex Pharmaceuticals, Inc.
Publication of HUP0101128A2 publication Critical patent/HUP0101128A2/hu
Publication of HUP0101128A3 publication Critical patent/HUP0101128A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

A találmány abban áll, hogy az emlősnek szájon át valamely, legalábbegy, a lipáz enzimet gátolni képes csoportot viselő polimernek a hatáskifejtéséhez szükséges mennyiségét adagolják. A leírás ismertetitovábbá az említett polimereket, az ezek előállításához használhatóköztitermékeket, valamint a mindezek előállítására szolgálóeljárásokat. Ó
HU0101128A 1998-01-09 1999-01-06 The use of lipase inhibiting polymers as an anti obesity medicament HUP0101128A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US537998A 1998-01-09 1998-01-09
US09/166,510 US6267952B1 (en) 1998-01-09 1998-10-05 Lipase inhibiting polymers
PCT/US1999/000195 WO1999034786A2 (en) 1998-01-09 1999-01-06 Lipase inhibiting polymers

Publications (2)

Publication Number Publication Date
HUP0101128A2 true HUP0101128A2 (hu) 2002-01-28
HUP0101128A3 HUP0101128A3 (en) 2003-01-28

Family

ID=26674279

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101128A HUP0101128A3 (en) 1998-01-09 1999-01-06 The use of lipase inhibiting polymers as an anti obesity medicament

Country Status (20)

Country Link
US (6) US6267952B1 (hu)
EP (1) EP1043982B1 (hu)
JP (1) JP2002500182A (hu)
KR (1) KR100620634B1 (hu)
CN (2) CN1636574A (hu)
AT (1) ATE308979T1 (hu)
AU (1) AU747016B2 (hu)
BR (1) BR9907233A (hu)
CA (1) CA2318416A1 (hu)
DE (1) DE69928219T2 (hu)
DK (1) DK1043982T3 (hu)
ES (1) ES2253872T3 (hu)
HK (1) HK1079706A1 (hu)
HU (1) HUP0101128A3 (hu)
IL (1) IL137098A (hu)
NO (1) NO20003511L (hu)
NZ (1) NZ505296A (hu)
PL (1) PL193453B1 (hu)
RU (1) RU2207861C2 (hu)
WO (1) WO1999034786A2 (hu)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
PE20010588A1 (es) * 1999-09-10 2001-06-23 Procter & Gamble Conjugados polimericos inhibidores de enzimas proteoliticas y lipoliticas
PE20010586A1 (es) * 1999-09-10 2001-06-23 Procter & Gamble Conjugados de polimeros funcionales que inhiben enzimas lipoliticas y/o proteoliticas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
CN1236764C (zh) * 2000-06-27 2006-01-18 霍夫曼-拉罗奇有限公司 制备组合物的方法
AU2001289696B2 (en) 2000-07-28 2006-07-06 Cheplapharm Arzneimittel Gmbh New use of lipase inhibitors
NZ523684A (en) 2000-07-28 2005-04-29 F New pharmaceutical composition
KR100494245B1 (ko) 2000-08-09 2005-06-13 에프. 호프만-라 로슈 아게 리파제 억제제의 용도
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03002299A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100545435B1 (ko) 2000-10-16 2006-01-24 에프. 호프만-라 로슈 아게 인돌린 유도체 및 5-ｈｔ2 수용체 리간드로서의 이들의 용도
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
ATE528303T1 (de) * 2000-12-21 2011-10-15 Vertex Pharma Pyrazoleverbindungen als proteinkinasehemmer
CA2432085C (en) 2000-12-27 2009-02-24 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
WO2002094789A1 (en) 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
ATE392897T1 (de) 2002-02-04 2008-05-15 Hoffmann La Roche Chinolinderivate als npy antagonisten
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
US6897033B2 (en) * 2002-02-19 2005-05-24 The Procter & Gamble Company Fungal lipase
RU2004129285A (ru) 2002-02-28 2005-10-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные тиазола в качестве антагонистов рецептора npy
ATE468336T1 (de) * 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
AU2003223930A1 (en) * 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
RU2296757C2 (ru) 2002-07-05 2007-04-10 Ф.Хоффманн-Ля Рош Аг Производные хиназолина
DE60308387T2 (de) * 2002-08-02 2007-09-20 Vertex Pharmaceuticals Inc., Cambridge Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
EP1539722A1 (en) 2002-08-07 2005-06-15 F. Hoffmann-La Roche Ag Thiazole derivatives
WO2004046211A1 (en) * 2002-11-19 2004-06-03 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CN100393718C (zh) 2003-08-12 2008-06-11 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的噻唑衍生物
MXPA06001570A (es) 2003-08-12 2006-05-15 Hoffmann La Roche Antagonistas del receptor de neuropeptido y (npy) 2-amino-5-benzoiltiazol.
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
WO2005056547A2 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US7462394B2 (en) * 2004-05-06 2008-12-09 Ppg Industries Ohio, Inc. Method of stabilizing metal pigments against gassing
US7943713B2 (en) * 2004-07-30 2011-05-17 Basf Aktiengesellschaft Polymeric boronic acid derivatives and their use for papermaking
BRPI0517434A (pt) * 2004-10-25 2008-10-07 Solvay Pharm Gmbh composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados
CN101171252B (zh) 2005-05-03 2011-06-01 霍夫曼-拉罗奇有限公司 作为5-ht2配体的四环氮杂吡嗪并二氢吲哚类化合物
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
BRPI0614834A2 (pt) 2005-08-18 2011-04-19 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e usos destas
EP1917259B1 (en) * 2005-08-18 2012-01-25 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
EP1948193B1 (en) * 2005-11-03 2015-01-07 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101316838B (zh) 2005-11-30 2013-01-30 霍夫曼-拉罗奇有限公司 用作h3调节剂的1,1-二氧代-硫代吗啉基吲哚基甲酮衍生物
KR20080076987A (ko) 2005-11-30 2008-08-20 에프. 호프만-라 로슈 아게 5-치환된 인돌-2-카복스아미드 유도체
CA2630314A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 1,5-substituted indol-2-yl amide derivatives
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
CA2631694A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
CA2631695A1 (en) 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-b]pyridine derivatives as h3 receptor modulators
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
US7902184B2 (en) 2006-05-30 2011-03-08 Hoffmann-La Roche Inc. Piperazinyl pyrimidine derivatives
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
MX2009004807A (es) * 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
CA2673353A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2679884A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
CN101668760B (zh) * 2007-03-09 2013-07-24 沃泰克斯药物股份有限公司 用作蛋白激酶抑制剂的氨基嘧啶类
JP2010523700A (ja) 2007-04-13 2010-07-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
EP2155730A2 (en) * 2007-05-02 2010-02-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009011810A (es) * 2007-05-02 2010-01-14 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
CN101801959A (zh) * 2007-05-02 2010-08-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
MX2009012719A (es) * 2007-05-24 2010-02-04 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
BRPI0814532A2 (pt) 2007-07-25 2015-01-27 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação dos receptores de h3, e uso desses compostos para a preparação de medicamentos.
TW200916468A (en) * 2007-07-31 2009-04-16 Vertex Pharma Process for preparing 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine and derivatives thereof
US8185398B2 (en) * 2007-12-31 2012-05-22 Intel-Ge Care Innovations Llc Reading device with shortcut read function
EP2323622A1 (en) * 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
EP3513660A1 (en) * 2010-03-13 2019-07-24 Eastpond Laboratories Limited Fat-binding compositions
CN102199172A (zh) * 2010-03-24 2011-09-28 金凯美(大连)医药科技有限公司 一种1-取代亚磷酰二氯的制备方法
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017227A (hu) 1969-12-27 1971-06-29
US4211765A (en) * 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
US3923972A (en) 1971-10-12 1975-12-02 Monsanto Co Method of lowering blood cholesterol level
IT1052819B (it) 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
US4265879A (en) 1977-09-13 1981-05-05 Monsanto Company Method for controlling blood triglycerides
US4302450A (en) 1979-01-15 1981-11-24 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4218443A (en) 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
AU7653081A (en) 1980-10-20 1982-04-29 Dow Chemical Company, The T-butylstyrene copolymers for controlling body weight of animals
US4432968A (en) 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
US5597810A (en) 1984-12-27 1997-01-28 Hoffman; Allan S. Method for reducing absorption of undesired lipids in the gastrointestinal tract
US5200183A (en) 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
US5089163A (en) 1989-01-30 1992-02-18 Lever Brothers Company, Division Of Conopco, Inc. Enzymatic liquid detergent composition
US4959179A (en) 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
US5063210A (en) 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5484777A (en) 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5674482A (en) 1989-08-14 1997-10-07 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Polymers with alkyl- or heteroalkyl -aryl backbone and pharmaceutical compositions incorporating same
WO1991003544A1 (en) 1989-08-29 1991-03-21 The Regents Of The University Of California Novel hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
US5308766A (en) 1989-08-29 1994-05-03 The Regents Of The University Of California Hydrolytic enzyme inhibitors/inactivators and methods for using same
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
US5260310A (en) 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
DK244090D0 (da) 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5137716A (en) 1990-11-15 1992-08-11 Weisenfeld Michael S Method of reducing weight in mammals
DK0835888T3 (da) 1992-01-14 2000-09-25 Hisamitsu Pharmaceutical Co En ikke-tværbundet anionbytterharpiks og farmaceutisk sammensætning indeholdende denne
CA2063499C (en) 1992-03-19 1996-06-18 Leon Edward St. Pierre Ingestible polymeric phosphonium salts for the lowering of blood cholesterol
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
DE59300925D1 (de) 1992-03-28 1995-12-21 Hoechst Ag Arzneimittel aus Polyhydroxymethylenderivaten, Verfahren zu deren Herstellung und Verwendung.
RU2066185C1 (ru) * 1993-01-11 1996-09-10 Институт пищевых веществ РАН Гиполипидемический энтеросорбент
US5624963A (en) 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5569452A (en) 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5474993A (en) 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
JPH0859458A (ja) 1994-08-25 1996-03-05 Zeria Pharmaceut Co Ltd インダン誘導体を含有する高脂血症治療剤
JP3532999B2 (ja) 1995-03-24 2004-05-31 株式会社ロッテ 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤
US5993675A (en) * 1997-12-31 1999-11-30 Hagerthy; Albert P. Fuel-water separator for marine and diesel engines
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
US6299868B1 (en) * 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
WO1999034787A2 (en) * 1998-01-09 1999-07-15 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US5942500A (en) * 1998-04-27 1999-08-24 Perry; Stephen C. Dietary composition to reduce dietary fats

Also Published As

Publication number Publication date
DK1043982T3 (da) 2006-02-13
WO1999034786A2 (en) 1999-07-15
US6352692B1 (en) 2002-03-05
AU747016B2 (en) 2002-05-09
US6875428B2 (en) 2005-04-05
IL137098A (en) 2006-07-05
BR9907233A (pt) 2000-10-17
EP1043982B1 (en) 2005-11-09
US6558657B1 (en) 2003-05-06
NZ505296A (en) 2002-12-20
EP1043982A2 (en) 2000-10-18
IL137098A0 (en) 2001-06-14
US20050085535A1 (en) 2005-04-21
JP2002500182A (ja) 2002-01-08
US6267952B1 (en) 2001-07-31
NO20003511D0 (no) 2000-07-07
CA2318416A1 (en) 1999-07-15
HUP0101128A3 (en) 2003-01-28
DE69928219D1 (de) 2005-12-15
PL193453B1 (pl) 2007-02-28
KR20010034012A (ko) 2001-04-25
RU2207861C2 (ru) 2003-07-10
KR100620634B1 (ko) 2006-09-13
US6572850B1 (en) 2003-06-03
CN1287489A (zh) 2001-03-14
DE69928219T2 (de) 2006-07-27
US20030185789A1 (en) 2003-10-02
AU2105699A (en) 1999-07-26
ATE308979T1 (de) 2005-11-15
NO20003511L (no) 2000-09-07
PL344022A1 (en) 2001-09-24
WO1999034786A3 (en) 2000-02-03
HK1079706A1 (zh) 2006-04-13
CN1636574A (zh) 2005-07-13
ES2253872T3 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
HUP0101128A2 (hu) Lipáz enzimeket gátló polimerek alkalmazása elhízás elleni gyógyszerként
DK1280541T3 (da) Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse af eller behandling af fordöjelsesforstyrrelser
HRP20070552T3 (en) Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
GEP20032920B (en) Inhibitors of Phospholipase Enzymes
MXPA02007915A (es) Mediador de lipido activado por aspirina.
ID28916A (id) Pengobatan ketagihan dan perilaku yang berkaitan dengan ketagihan
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
BRPI0412254A (pt) produtos aril-heteroaromáticos, composições que os contêm e utilização
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
HUP0300725A2 (hu) Az inzulinrezisztencia-szindróma kezelése CGMP PDE5 inhibitorokkal
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
HUP0003982A1 (hu) Renin-angiotenzin inhibitorok alkalmazása, hipoxia vagy gyengült metabolikus funkció kezelésére alkalmas gyógyszerkészítmények előállítására
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
SI1730315T1 (sl) Polimorfizmi v genu NOD2/CARD15
HUP0303900A2 (hu) Az arteminnek, a GDNF ligandum család egy tagjának új alkalmazása
ES2194003T3 (es) Huperzina a racemica.
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
CO5190668A1 (es) Composiciones de beta lactama especificamente cefuroxima- axetil en una forma no gelatinosaal contacto con un liquido acuoso, util para la produccion de composiciones farmaceuticas que comprende cefuroxina-axetil como un ingrediente activo
DK1220852T3 (da) Substituerede diazepaner
WO2001087239A3 (en) Methods of affecting laminin 5 processing
BR9812368A (pt) 2-aminotetralinas, processo para sua preparação, e composições farmacêuticas, para a prevenção e tratamento terapêutico de patologias inflamatórias e/ou autoimunes
IL139303A0 (en) Treatment of arthritis and other similar conditions
FR2885812A1 (fr) Medicament a base de laminarine ou d'oligolaminarines pour le traitement de la septicemie et du choc septique